Xu YP, Yang M. Advancement in treatment and diagnosis of pancreatic cancer with radiopharmaceuticals. World J Gastrointest Oncol 2016; 8(2): 165-172 [PMID: 26909131 DOI: 10.4251/wjgo.v8.i2.165]
Corresponding Author of This Article
Min Yang, Professor, Key Laboratory of Nuclear Medicine, Ministry of Health, Jiangsu Key Laboratory of Molecular Nuclear Medicine, Jiangsu Institute of Nuclear Medicine, 20 Qianrong Road, Wuxi 214063, Jiangsu Province, China. yangmin@jsinm.org
Research Domain of This Article
Oncology
Article-Type of This Article
Topic Highlight
Open-Access Policy of This Article
This article is an open-access article which was selected by an in-house editor and fully peer-reviewed by external reviewers. It is distributed in accordance with the Creative Commons Attribution Non Commercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited and the use is non-commercial. See: http://creativecommons.org/licenses/by-nc/4.0/
Baishideng Publishing Group Inc, 7041 Koll Center Parkway, Suite 160, Pleasanton, CA 94566, USA
Share the Article
Xu YP, Yang M. Advancement in treatment and diagnosis of pancreatic cancer with radiopharmaceuticals. World J Gastrointest Oncol 2016; 8(2): 165-172 [PMID: 26909131 DOI: 10.4251/wjgo.v8.i2.165]
World J Gastrointest Oncol. Feb 15, 2016; 8(2): 165-172 Published online Feb 15, 2016. doi: 10.4251/wjgo.v8.i2.165
Advancement in treatment and diagnosis of pancreatic cancer with radiopharmaceuticals
Yu-Ping Xu, Min Yang
Yu-Ping Xu, Min Yang, Key Laboratory of Nuclear Medicine, Ministry of Health, Jiangsu Key Laboratory of Molecular Nuclear Medicine, Jiangsu Institute of Nuclear Medicine, Wuxi 214063, Jiangsu Province, China
Author contributions: Xu YP collected the material, prepared the manuscript and approved the final version; Yang M prepared the manuscript and approved the final version.
Supported by National Natural Science Foundation, Nos. 81171399, 51473071, 81101077, 21401084, 81401450 and 81472749; Jiangsu Province Foundation, Nos. BE2014609, BE2012622, BL2012031 and BM2012066; and Wuxi Foundation, No. CSZ0N1320.
Conflict-of-interest statement: The authors do not have any possible conflicts of interest.
Correspondence to: Min Yang, Professor, Key Laboratory of Nuclear Medicine, Ministry of Health, Jiangsu Key Laboratory of Molecular Nuclear Medicine, Jiangsu Institute of Nuclear Medicine, 20 Qianrong Road, Wuxi 214063, Jiangsu Province, China. yangmin@jsinm.org
Telephone: +86-510-85508862 Fax: +86-510-85513113
Received: April 28, 2015 Peer-review started: May 5, 2015 First decision: July 21, 2015 Revised: November 26, 2015 Accepted: December 17, 2015 Article in press: December 18, 2015 Published online: February 15, 2016 Processing time: 280 Days and 2.6 Hours
Abstract
Pancreatic cancer (PC) is a major health problem. Conventional imaging modalities show limited accuracy for reliable assessment of the tumor. Recent researches suggest that molecular imaging techniques with tracers provide more biologically relevant information and are benefit for the diagnosis of the cancer. In addition, radiopharmaceuticals also play more important roles in treatment of the disease. This review summaries the advancement of the radiolabeled compounds in the theranostics of PC.
Core tip: This review describes the development of radiopharmaceuticals in diagnosis and therapy of pancreatic cancer. We herein discuss the role of the radiolabeled compounds in the preoperative diagnosis, staging, post-therapeutic monitoring, prognosis and the treatment of the disease.
